RARE
Ultragenyx Pharmaceutical Inc.
$21.59
-1.46%
$2.1B
No data for this timeframe.
Vol
Market Cap$2.1B
Cap SizeMid Cap
Inst. Holders9 funds
Inst. Value$429.7M
Inst. Activity6 buys / 1 sells
Insider Activity0B / 14S
Insider Net $-$2.9M
Reddit Sentiment50° Neutral
SEC Reports5
Recent Activity
Sep 19, 2026
fda_pdufa
PDUFA: RARE — UX111 in Sanfilippo syndrome type A (MPS IIIA) — 2026-09-19
FDA target action date 2026-09-19 for RARE (Ultragenyx Pharmaceutical Inc.). Drug: UX111. Indication
Jun 1, 2026
Insider
Horn Howard sold 4,653 shares
Chief Financial Officer @ $23.77 ($110.6K)
May 18, 2026
Insider
SULIMAN SHEHNAAZ sold 5,740 shares
Director @ $25.12 ($144.2K)
May 14, 2026
Insider
Dunsire Deborah sold 7,751 shares
Director @ $0.00 ($0.00)
May 6, 2026
SEC
Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past
CLUSTER — Impact 2/10
May 5, 2026
SEC
Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expe
PRESS-RELEASE — Impact 6/10
Apr 2, 2026
SEC
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Applicat
8-K — Impact 8/10
Inst.
FMR LLC — TRIM
2,666,249 shares ($61.3M)
Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$52.05 (Oct 2024)
Current $22.79
Low $25.00
Median $48.00
High $96.00
19 analysts
$25.00
$96.00
Analyst Ratings
8Strong Buy
14Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 22, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Oct 21, 2024 | TD Cowen | MAINTAIN | Buy → Buy |
| Oct 1, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
| Sep 26, 2024 | RBC Capital | REITERATE | Outperform → Outperform |
| Sep 20, 2024 | Cantor Fitzgerald | REITERATE | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.14 ▼ -0.6% | $-1.46 — $-0.78 | 2% YoY | 4 |
| Next Q | $-0.95 ▲ +6.7% | $-1.38 — $-0.63 | 48% YoY | 3 |
| Current FY | $-4.24 ▲ +5.0% | $-4.41 — $-4.12 | 27% YoY | 4 |
| Next FY | $0.97 ▲ +7682.5% | $-1.60 — $5.61 | 123% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past
May 6, 2026
BEARISH
PRESS-RELEASE
6/10
Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expe
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $236.1M | — |
| FMR LLC | $61.3M | TRIM |
| MORGAN STANLEY | $42.0M | DOUBLED |
| NORGES BANK | $29.0M | NEW |
| BANK OF AMERICA CORP | $27.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Horn Howard | SELL | $110.6K |
| May 18, 2026 | SULIMAN SHEHNAAZ | SELL | $144.2K |
| May 14, 2026 | Dunsire Deborah | A | $0.00 |
| May 14, 2026 | Dunsire Deborah | A | $0.00 |
| May 14, 2026 | WELCH DANIEL | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $429.7M total value (18,683,949 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 6 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 10,263,815 | $236.1M | 54.9% | — |
| 2 | FMR LLC | 2,666,249 | $61.3M | 14.3% | TRIM -63.4% |
| 3 | MORGAN STANLEY | 1,826,295 | $42.0M | 9.8% | DOUBLED +100.7% |
| 4 | NORGES BANK | 1,261,026 | $29.0M | 6.7% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 1,213,928 | $27.9M | 6.5% | ADD +85.3% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 598,924 | $13.8M | 3.2% | NEW |
| 7 | TWO SIGMA INVESTMENTS, LP | 424,049 | $9.8M | 2.3% | ADD +30.0% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 366,100 | $8.4M | 2.0% | DOUBLED +1571.7% |
| 9 | WELLS FARGO & COMPANY/MN | 63,563 | $1.5M | 0.3% | DOUBLED +154.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | TRIM | 7,283,296 | 2,666,249 | -63.4% | $61.3M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 910,183 | 1,826,295 | +100.7% | $42.0M | 2025-Q4 |
| NORGES BANK | NEW | — | 1,261,026 | — | $29.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 655,021 | 1,213,928 | +85.3% | $27.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 326,180 | 424,049 | +30.0% | $9.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,900 | 366,100 | +1571.7% | $8.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 24,948 | 63,563 | +154.8% | $1.5M | 2025-Q4 |
| FMR LLC | DOUBLED | 2,604,588 | 7,283,296 | +179.6% | $219.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 638,879 | 910,183 | +42.5% | $27.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 576,901 | 326,180 | -43.5% | $9.8M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 17,440 | 24,948 | +43.1% | $750.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 208,300 | 21,900 | -89.5% | $658.8K | 2025-Q3 |
| NORGES BANK | EXIT | 983,638 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | DOUBLED | 381,422 | 2,604,588 | +582.9% | $94.7M | 2025-Q2 |
| NORGES BANK | NEW | — | 983,638 | — | $35.8M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 527,980 | 672,390 | +27.4% | $24.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 299,600 | 208,300 | -30.5% | $7.6M | 2025-Q2 |
| UBS Group AG | ADD | 325,651 | 469,482 | +44.2% | $17.0M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 30,371 | 17,269 | -43.1% | $625.3K | 2025-Q1 |
| NORGES BANK | EXIT | 961,794 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 467,836 | 598,189 | +27.9% | $25.2M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 105,253 | 374,979 | +256.3% | $15.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 93,069 | 325,651 | +249.9% | $13.7M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 182,100 | 254,700 | +39.9% | $10.7M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 594,521 | — | $33.0M | 2024-Q3 |
15 unique insiders with 14 transactions. Net insider value: -$2.9M ($0.00 bought, $2.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Horn Howard | Chief Financial Officer | SELL | 4,653 | $23.77 | $110.6K |
| May 18, 2026 | SULIMAN SHEHNAAZ | Director | SELL | 5,740 | $25.12 | $144.2K |
| May 14, 2026 | Dunsire Deborah | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | Dunsire Deborah | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | WELCH DANIEL G | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | WELCH DANIEL G | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | NARACHI MICHAEL | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | NARACHI MICHAEL | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | Sanders Corazon (Corsee) D. | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | Sanders Corazon (Corsee) D. | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | Ray Amrit | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | Ray Amrit | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | SULIMAN SHEHNAAZ | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | SULIMAN SHEHNAAZ | Director | A | 14,058 | $0.00 | $0.00 |
| May 14, 2026 | Fust Matthew K | Director | A | 7,751 | $0.00 | $0.00 |
| May 14, 2026 | Fust Matthew K | Director | A | 14,058 | $0.00 | $0.00 |
| May 5, 2026 | Crombez Eric | EVP and Chief Medical Officer | SELL | 344 | $24.96 | $8.6K |
| May 1, 2026 | Horn Howard | Chief Financial Officer | SELL | 4,683 | $24.90 | $116.6K |
| Apr 22, 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | A | 20,241 | $0.00 | $0.00 |
| Apr 22, 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | A | 7,348 | $0.00 | $0.00 |
| Apr 16, 2026 | Horn Howard | Chief Financial Officer | A | 34,674 | $0.00 | $0.00 |
| Apr 16, 2026 | Horn Howard | Chief Financial Officer | A | 59,952 | $0.00 | $0.00 |
| Apr 16, 2026 | Crombez Eric | EVP and Chief Medical Officer | A | 34,674 | $0.00 | $0.00 |
| Apr 16, 2026 | Crombez Eric | EVP and Chief Medical Officer | A | 59,952 | $0.00 | $0.00 |
| Apr 16, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | 49,960 | $0.00 | $0.00 |
| Apr 16, 2026 | Harris Erik | EVP & Chief Commercial Officer | A | 28,895 | $0.00 | $0.00 |
| Apr 16, 2026 | Harris Erik | EVP & Chief Commercial Officer | A | 49,960 | $0.00 | $0.00 |
| Apr 16, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | 28,895 | $0.00 | $0.00 |
| Apr 16, 2026 | Pinion John Richard | See Remarks | A | 23,116 | $0.00 | $0.00 |
| Apr 16, 2026 | Pinion John Richard | See Remarks | A | 79,936 | $0.00 | $0.00 |
| Apr 16, 2026 | Huang Dennis Karl | See Remarks | A | 23,116 | $0.00 | $0.00 |
| Apr 16, 2026 | Huang Dennis Karl | See Remarks | A | 79,936 | $0.00 | $0.00 |
| Apr 16, 2026 | KAKKIS EMIL D | President & CEO | A | 76,745 | $0.00 | $0.00 |
| Apr 16, 2026 | KAKKIS EMIL D | President & CEO | A | 132,693 | $0.00 | $0.00 |
| Apr 1, 2026 | Horn Howard | Chief Financial Officer | SELL | 4,683 | $20.97 | $98.2K |
| Mar 10, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | SELL | 3,508 | $22.67 | $79.5K |
| Mar 6, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | SELL | 6,018 | $21.40 | $128.8K |
| Mar 3, 2026 | Horn Howard | Chief Financial Officer | SELL | 1,635 | $22.40 | $36.6K |
| Mar 2, 2026 | Pinion John Richard | See Remarks | SELL | 10,029 | $22.80 | $228.7K |
| Mar 2, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | SELL | 8,135 | $22.80 | $185.5K |
| Mar 2, 2026 | Horn Howard | Chief Financial Officer | SELL | 5,290 | $22.80 | $120.6K |
| Mar 2, 2026 | Huang Dennis Karl | See Remarks | F | 999 | $23.39 | $23.4K |
| Mar 2, 2026 | Harris Erik | EVP & Chief Commercial Officer | SELL | 10,539 | $22.80 | $240.3K |
| Mar 2, 2026 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | F | 148 | $23.39 | $3.5K |
| Mar 2, 2026 | Crombez Eric | EVP and Chief Medical Officer | SELL | 7,029 | $22.80 | $160.3K |
| Mar 2, 2026 | KAKKIS EMIL D | President & CEO | SELL | 54,404 | $22.80 | $1.2M |
| Mar 1, 2026 | Pinion John Richard | See Remarks | A | 11,137 | $0.00 | $0.00 |
| Mar 1, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | A | 11,137 | $0.00 | $0.00 |
| Mar 1, 2026 | Horn Howard | Chief Financial Officer | A | 6,143 | $0.00 | $0.00 |
| Mar 1, 2026 | Huang Dennis Karl | See Remarks | A | 11,137 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 4.6/10.
NEUTRAL
CLUSTER
2/10
Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transac
May 6, 2026
BEARISH
PRESS-RELEASE
6/10
Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46
May 5, 2026
BULLISH
8-K
8/10
Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biolog
Apr 2, 2026
NEUTRAL
DEFA14A
2/10
Ultragenyx Pharmaceutical Inc. (RARE) has filed a definitive additional proxy soliciting material (D
Mar 27, 2026
BEARISH
CLUSTER
5/10
Multiple executives at Ultragenyx Pharmaceutical, including the CFO and Chief Medical Officer, condu
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Oct 2024): 88% buy across 25 analysts — 8 strong buy, 14 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Oct 2024. No current recommendation available.
$52.05 mean target (Oct 2024)
$25.00 Low
$96.00 High
| Metric | Value |
|---|---|
| Current Price | $22.79 |
| Target Low | $25.00 |
| Target Mean | $52.05 |
| Target Median | $48.00 |
| Target High | $96.00 |
| # Analysts | 19 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.14 | $-1.46 | $-0.78 | 2.3% | -0.6% | 0↑ 3↓ | $0.2B | 9.2% | 4 |
| Next Q 2026-09-30 |
$-0.95 | $-1.38 | $-0.63 | 47.6% | +6.7% | 0↑ 3↓ | $0.2B | 15.0% | 3 |
| Current FY 2026-12-31 |
$-4.24 | $-4.41 | $-4.12 | 27.2% | +5.0% | 0↑ 2↓ | $0.7B | 10.2% | 4 |
| Next FY 2027-12-31 |
$0.97 | $-1.60 | $5.61 | 122.7% | +7682.5% | 0↑ 1↓ | $1.0B | 32.7% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.144 | |
| 7d ago | $-1.222 | +0.078 |
| 30d ago | $-1.137 | -0.006 |
| 60d ago | $-1.129 | -0.014 |
| 90d ago | $-1.070 | -0.074 |
17 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Oct 22, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Oct 21, 2024 | TD Cowen | MAINTAIN | Buy | Buy |
| Oct 1, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 26, 2024 | RBC Capital | REITERATE | Outperform | Outperform |
| Sep 20, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 16, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 5, 2024 | Barclays | MAINTAIN | Overweight | Overweight |
| Aug 2, 2024 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Aug 2, 2024 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Aug 2, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Aug 2, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jul 23, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jul 22, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Jul 18, 2024 | Wedbush | REITERATE | Neutral | Neutral |
| Jun 12, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Jun 6, 2024 | Goldman Sachs | UPGRADE | Neutral | Buy |
| May 31, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| May 31, 2024 | B of A Securities | MAINTAIN | Buy | Buy |
| May 31, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 31, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| May 31, 2024 | Stifel | MAINTAIN | Buy | Buy |
| May 31, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| May 6, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 3, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| May 3, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Apr 24, 2024 | TD Cowen | MAINTAIN | Buy | Buy |
| Apr 22, 2024 | RBC Capital | INITIATE | — | Outperform |
| Apr 17, 2024 | Wedbush | REITERATE | Neutral | Neutral |
| Apr 16, 2024 | Wedbush | REITERATE | Neutral | Neutral |
| Apr 5, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Mar 18, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 27, 2024 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 27, 2024 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 21, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 16, 2024 | Wedbush | MAINTAIN | Neutral | Neutral |
| Feb 15, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Jan 30, 2024 | Baird | MAINTAIN | Outperform | Outperform |
| Jan 19, 2024 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Dec 8, 2023 | Wells Fargo | INITIATE | — | Overweight |
| Nov 3, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Oct 25, 2023 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Oct 10, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Sep 25, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 4, 2023 | Morgan Stanley | REITERATE | Overweight | Overweight |
| Aug 1, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 7, 2023 | Citigroup | MAINTAIN | Buy | Buy |
| Jun 6, 2023 | Evercore ISI Group | UPGRADE | In-Line | Outperform |
| Jun 6, 2023 | Wedbush | MAINTAIN | Neutral | Neutral |
| May 8, 2023 | Wedbush | MAINTAIN | — | Neutral |
| May 5, 2023 | Citigroup | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 14 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 8 | 15 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 8 | 15 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% | |
| Feb 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% | |
| Jan 1, 2026 | 9 | 16 | 2 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 24, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Sep 19, 2026
fda_pdufa
PDUFA: RARE — UX111 in Sanfilippo syndrome type A (MPS IIIA) — 2026-09-19
FDA target action date 2026-09-19 for RARE (Ultragenyx Pharmaceutical Inc.). Drug: UX111. Indication: Sanfilippo syndrome type A (MPS IIIA). PDUFA tar
Aug 23, 2026
fda_pdufa
PDUFA: RARE — DTX401 in glycogen storage disease type Ia (GSDIa) — 2026-08-23
FDA target action date 2026-08-23 for RARE (Ultragenyx Pharmaceutical Inc.). Drug: DTX401. Indication: glycogen storage disease type Ia (GSDIa). PDUFA
Jun 9, 2026
short_volume
Short Volume: RARE — 56.7% short (0.3M / 0.6M)
Short: 339,197 | Exempt: 43 | TRF Vol: 597,825 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
other
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
<p>NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the devel
Jun 3, 2026
Clinical Trial
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
Phase Phase 2 — COMPLETED
Jun 3, 2026
short_volume
Short Volume: RARE — 64.7% short (0.4M / 0.7M)
Short: 425,949 | Exempt: 0 | TRF Vol: 657,993 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: RARE — 60.3% short (0.4M / 0.6M)
Short: 362,534 | Exempt: 0 | TRF Vol: 601,513 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: RARE — 69.0% short (0.4M / 0.6M)
Short: 390,643 | Exempt: 9 | TRF Vol: 566,004 | Short Ratio: 69.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: RARE — 60.3% short (0.3M / 0.5M)
Short: 317,615 | Exempt: 0 | TRF Vol: 526,932 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
May 22, 2026
other
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the develo
May 20, 2026
short_volume
Short Volume: RARE — 61.8% short (0.3M / 0.5M)
Short: 326,985 | Exempt: 2,526 | TRF Vol: 529,485 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RARE — 66.8% short (0.4M / 0.7M)
Short: 442,832 | Exempt: 298 | TRF Vol: 663,299 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: RARE — 1.9M shares, 46,695 trades
Week starting 2026-05-18. Total ATS volume: 1,942,042 shares across 46,695 trades.
May 11, 2026
dark_pool
Dark Pool: RARE — 1.6M shares, 40,256 trades
Week starting 2026-05-11. Total ATS volume: 1,639,179 shares across 40,256 trades.
May 8, 2026
short_volume
Short Volume: RARE — 65.9% short (0.3M / 0.5M)
Short: 344,817 | Exempt: 0 | TRF Vol: 523,358 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: RARE — 60.9% short (0.4M / 0.7M)
Short: 399,377 | Exempt: 0 | TRF Vol: 655,801 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
Clinical Trial
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Apr 1, 2026
Clinical Trial
A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Phase Phase 3 — COMPLETED